Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Aprea Therapeutics

Clinical trials sponsored by Aprea Therapeutics, explained in plain language.

Aprea Therapeutics APRE NASDAQ

A clinical-stage biopharmaceutical company developing cancer therapies targeting p53 mutations.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Completed 1

New hope for advanced cancer: APR-1051 enters first human trial

Disease control Recruiting now

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

Phase: PHASE1 • Sponsor: Aprea Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC